Alnylam Advances Development Candidate for ALN-AAT, a Subcutaneously Administered RNAi Therapeutic Targeting Alpha-1 Antitrypsin (AAT) in Development for the Treatment of AAT Deficiency-Associated Liver Disease

[Business Wire] – Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate for ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin in development for the treatment of AAT d more

View todays social media effects on ALNY

View the latest stocks trending across Twitter. Click to view dashboard

See who Alnylam is hiring next, click here to view